Real-world data of first-line treatment with pembrolizumab for non-small cell lung cancer with high PD-L1 expression (HOT/NJLCG2001)

被引：0

作者：

Yokouchi, H. ^{[1
]}

Mizugaki, H. ^{[2
]}

Ikezawa, Y. ^{[3
]}

Morita, R. ^{[4
]}

Tateishi, K. ^{[5
]}

Yokoo, K. ^{[6
]}

Sumi, T. ^{[7
]}

Kikuchi, H. ^{[8
]}

Nakamura, A. ^{[9
]}

Kobayashi, M. ^{[10
]}

Aso, M. ^{[11
]}

Tsukita, Y. ^{[12
]}

Yoshiike, F. ^{[13
]}

Furuta, M. ^{[14
]}

Tanaka, H. ^{[15
]}

Sekikawa, M. ^{[16
]}

Hachiya, T. ^{[17
]}

Nakamura, K. ^{[18
]}

Kitamura, Y. ^{[19
]}

机构：

[1] Hokkaido Canc Ctr, Dept Resp Med, Fukushima, Japan

[2] Japanese Fdn Canc Res, Canc Immunotherapy Dev, Adv Med Dev Ctr, Canc Inst Hosp, Koto Ku, Tokyo, Japan

[3] Oji Gen Hosp, Dept Resp Med, Tomakomai, Japan

[4] Akita Kousei Med Ctr, Thorac Oncol, Akita, Nishibukuro, Japan

[5] Shinshu Univ, Sch Med, 3-1-1 Asahi, Matsumoto, Nagano, Japan

[6] Teine Keijinkai Hosp, Dept Resp Med, Sapporo, Hokkaido, Japan

[7] Hakodate Goryoukaku Hosp, Dept Resp Med, Hakodate, Hokkaido, Japan

[8] JA Hokkaido Kouseiren Obihiro Kosei Gen Hosp, Dept Resp Med, Obihiro, Hokkaido, Japan

[9] Sendai Kousei Hosp, Dept Resp Med, Sendai, Miyagi, Japan

[10] Miyagi Canc Ctr, Resp Med, Natori, Miyagi, Japan

[11] Yamagata Prefectural Cent Hosp, Pulm Med, Yamagata, Japan

[12] Tohoku Univ, Dept Resp Med, Sendai, Miyagi, Japan

[13] Nagano Municipal Hosp, Dept Resp Med, Nagano, Japan

[14] Hokkaido Univ Hosp, Dept Resp Med, Sapporo, Hokkaido, Japan

[15] Hirosaki Univ, Dept Resp Med, Hirosaki, Aomori, Japan

[16] Steel Mem Muroran Hosp, Dept Resp Med, Muroran, Hokkaido, Japan

[17] Suwa Red Cross Hosp, Dept Resp Med, Suwa, Japan

[18] Natl Hosp Org Asahikawa Med Ctr, Dept Resp Med, Asahikawa, Hokkaido, Japan

[19] Kushiro City Gen Hosp, Dept Resp Med, Kushiro, Japan

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷

关键词：

D O I：

10.1016/j.annonc.2022.10.373

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

335P

引用

页码：S1574 / S1574

页数：1

共 50 条

[1] Real-world data of first-line treatment with pembrolizumab for NSCLC with high PD-L1 expression (HOT/NJLCG2001)
Kitamura, Yasuo
Mizugaki, Hidenori
Ikezawa, Yasuyuki
Morita, Ryo
Tateishi, Kazunari
Yokoo, Keiki
Sumi, Toshiyuki
Kikuchi, Hajime
Nakamura, Atsushi
Kobayashi, Maki
Aso, Mari
Kimura, Nozomu
Yoshiike, Fumiaki
Furuta, Megumi
Tanaka, Hisashi
Sekikawa, Motoki
Hachiya, Tsutomu
Nakamura, Keiichi
Oizumi, Satoshi
ANNALS OF ONCOLOGY, 2022, 33 : S524 - S524
[2] Real-world data of first-line treatment with pembrolizumab for NSCLC with high PD-L1 expression (HOT/NJLCG2001 secondary report)
Tateishi, Kazunari
Mizugaki, Hidenori
Ikezawa, Yasuyuki
Morita, Ryo
Yokoo, Keiki
Sumi, Toshiyuki
Kikuchi, Hajime
Kitamura, Yasuo
Nakamura, Atsushi
Kobayashi, Maki
Aso, Mari
Kimura, Nozomu
Yoshiike, Fumiaki
Furuta, Megumi
Tanaka, Hisashi
Sekikawa, Motoki
Hashiya, Tsutomu
Fujita, Yuka
Oizumi, Satoshi
ANNALS OF ONCOLOGY, 2023, 34 : S1394 - S1394
[3] Real-world data of first-line treatment with pembrolizumab for highly PD-L1 expressing NSCLC (HOT/NJLCG2001)
Nakamura, A.
Mizugaki, H.
Ikezawa, Y.
Morita, R.
Tateishi, K.
Yokoo, K.
Sumi, T.
Kikuchi, H.
Kitamura, Y.
Morita, M.
Aso, M.
Tsukita, Y.
Yoshiike, F.
Furuta, M.
Tanaka, H.
Sekikawa, M.
Hachiya, T.
Nakamura, K.
Yokouchi, H.
ANNALS OF ONCOLOGY, 2021, 32 : S1008 - S1008
[4] Real-world first-line treatment with pembrolizumab for non-small cell lung carcinoma with high PD-L1 expression: Updated analysis
Ikezawa, Yasuyuki
Morita, Ryo
Mizugaki, Hidenori
Tateishi, Kazunari
Yokoo, Keiki
Sumi, Toshiyuki
Kikuchi, Hajime
Kitamura, Yasuo
Nakamura, Atsushi
Kobayashi, Maki
Aso, Mari
Kimura, Nozomu
Yoshiike, Fumiaki
Megumi, Furuta
Tanaka, Hisashi
Sekikawa, Motoki
Hachiya, Tsutomu
Nakamura, Keiichi
Hommura, Fumihiro
Sukoh, Noriaki
Ito, Kenichiro
Kikuchi, Takashi
Agatsuma, Toshihiko
Yokouchi, Hiroshi
CANCER MEDICINE, 2024, 13 (14):
[5] Real-World Efficacy of First-Line Pembrolizumab in Patients with Advanced PD-L1 High Non-Small Cell Lung Cancer in Argentina
Kuzminin, A.
Minatta, N.
Bluthgen, M.
Rizzo, M.
Naveira, M.
Wainsztein, V.
Lupinacci, L.
Rizzi, M.
Faura, M.
Perfetti, A.
Recondo, G., Jr.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S589 - S590
[6] Real-World Efficacy of First-Line Pembrolizumab in Patients With Advanced or Recurrent Non-Small-Cell Lung Cancer and High PD-L1 Tumor Expression
Tambo, Yuichi
Sone, Takashi
Shibata, Kazuhiko
Nishi, Kouichi
Shirasaki, Hiroki
Yoneda, Taro
Araya, Tomoyuki
Kase, Kazumasa
Nishikawa, Shingo
Kimura, Hideharu
Kasahara, Kazuo
CLINICAL LUNG CANCER, 2020, 21 (05) : E366 - E379
[7] First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
Zhou, Yixin
Lin, Zuan
Zhang, Xuanye
Chen, Chen
Zhao, Hongyun
Hong, Shaodong
Zhang, Li
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[8] Current status of first-line treatment with pembrolizumab for non-small-cell lung cancer with high PD-L1 expression
Ikezawa, Yasuyuki
Mizugaki, Hidenori
Morita, Ryo
Tateishi, Kazunari
Yokoo, Keiki
Sumi, Toshiyuki
Kikuchi, Hajime
Kitamura, Yasuo
Nakamura, Atsushi
Kobayashi, Maki
Aso, Mari
Kimura, Nozomu
Yoshiike, Fumiaki
Furuta, Megumi
Tanaka, Hisashi
Sekikawa, Motoki
Hachiya, Tsutomu
Nakamura, Keiichi
Shimokawa, Mototsugu
Oizumi, Satoshi
CANCER SCIENCE, 2022, 113 (06) : 2109 - 2117
[9] Real World Efficacy of Pembrolizumab of as a 1st Line Treatment in Metastatic Non-Small Cell Lung Cancer with PD-L1 High Expression
Kasahara, K.
Sone, T.
Nishi, K.
Shibata, K.
Araya, T.
Shirasaki, H.
Yoneda, T.
Kase, K.
Nishikawa, S.
Kimura, H.
Tambo, Y.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S460 - S460
[10] First-line pembrolizumab monotherapy in metastatic PD-L1 positive non-small cell lung cancer: A real-world analysis of time on treatment in US community oncology practices
Velcheti, V.
Chandwani, S.
Chen, X.
Pietanza, M. C.
Burke, T.
ANNALS OF ONCOLOGY, 2018, 29 : 18 - 18

← 1 2 3 4 5 →